JOP20200290A1 - تركيبة RUR20kD-IL-2 الانتقائية لمحفز TREG وتركيبات ذات صلة - Google Patents
تركيبة RUR20kD-IL-2 الانتقائية لمحفز TREG وتركيبات ذات صلةInfo
- Publication number
- JOP20200290A1 JOP20200290A1 JOP/2020/0290A JOP20200290A JOP20200290A1 JO P20200290 A1 JOP20200290 A1 JO P20200290A1 JO P20200290 A JOP20200290 A JO P20200290A JO P20200290 A1 JOP20200290 A1 JO P20200290A1
- Authority
- JO
- Jordan
- Prior art keywords
- rur20kd
- compositions
- related compositions
- treg stimulator
- selective treg
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 210000003162 effector t lymphocyte Anatomy 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 210000003289 regulatory T cell Anatomy 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Transplantation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862674244P | 2018-05-21 | 2018-05-21 | |
| PCT/US2019/033100 WO2019226538A1 (en) | 2018-05-21 | 2019-05-20 | SELECTIVE TREG STIMULATOR RUR20kD-IL-2 AND RELATED COMPOSITIONS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JOP20200290A1 true JOP20200290A1 (ar) | 2020-11-15 |
Family
ID=67002369
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOP/2020/0290A JOP20200290A1 (ar) | 2018-05-21 | 2019-05-20 | تركيبة RUR20kD-IL-2 الانتقائية لمحفز TREG وتركيبات ذات صلة |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20210205413A1 (es) |
| EP (1) | EP3796940A1 (es) |
| JP (2) | JP7235772B2 (es) |
| KR (1) | KR20210002577A (es) |
| CN (1) | CN112399859A (es) |
| AU (2) | AU2019274409B2 (es) |
| BR (1) | BR112020021564A2 (es) |
| CA (1) | CA3100204A1 (es) |
| CL (1) | CL2020003008A1 (es) |
| CO (1) | CO2020014510A2 (es) |
| CR (1) | CR20200546A (es) |
| DO (1) | DOP2020000212A (es) |
| EA (1) | EA202092489A1 (es) |
| EC (1) | ECSP20074392A (es) |
| IL (1) | IL278528B1 (es) |
| JO (1) | JOP20200290A1 (es) |
| PE (1) | PE20211307A1 (es) |
| PH (1) | PH12020551976A1 (es) |
| SG (1) | SG11202011242SA (es) |
| WO (1) | WO2019226538A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115315436A (zh) * | 2020-01-10 | 2022-11-08 | 明峰治疗股份公司 | 修饰的il-2多肽及其用途 |
| US20230102464A1 (en) * | 2020-01-15 | 2023-03-30 | Jenkem Technology Co., Ltd. (Tianjin) | Method for preparing pegylated biomolecule with controllable binding sites |
| CN113121670B (zh) * | 2020-01-15 | 2022-11-22 | 天津键凯科技有限公司 | 二取代peg化白细胞介素2及其制备方法、应用 |
| US20230272001A1 (en) * | 2020-05-22 | 2023-08-31 | Merck Sharp & Dohme Llc | Novel processes for preparing conjugates of the il-2 protein |
| TW202228784A (zh) | 2020-09-23 | 2022-08-01 | 奧地利商艾柏力維亞生技有限公司 | 用以於一患者中螯合非預期的抗ｐｅｇ抗體的化合物 |
| US20230414720A1 (en) * | 2020-11-23 | 2023-12-28 | University Of Florida Research Foundation, Incorporated | Use of insulin-like growth factors with gamma-chain cytokines to induce homeostatic proliferation of lymphocytes |
| WO2023114833A1 (en) | 2021-12-14 | 2023-06-22 | Eli Lilly And Company | Dosing regimens for selective treg stimulator rur20kd-il-2 and related compositions |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4401756A (en) | 1981-04-14 | 1983-08-30 | Immunex Corporation | Process for preparing human interleukin 2 |
| US4569790A (en) | 1984-03-28 | 1986-02-11 | Cetus Corporation | Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions |
| US5116943A (en) | 1985-01-18 | 1992-05-26 | Cetus Corporation | Oxidation-resistant muteins of Il-2 and other protein |
| US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| US5153310A (en) | 1989-02-28 | 1992-10-06 | Du Pont Merck Pharmaceutical Company | Il-2 analogs containing n-linked glycosylation sites |
| US5635597A (en) | 1994-05-27 | 1997-06-03 | Affymax Technologies, N.V. | Peptides that bind IL-2 receptors |
| US6168785B1 (en) | 1998-07-16 | 2001-01-02 | Institut Pasteur | Biological applications of new peptides of IL-2 and derivatives and use as therapeutic agents |
| FR2826365B1 (fr) | 2001-06-20 | 2003-09-26 | Oreal | Compositions cosmetiques photoprotectrices contenant des derives amides, sulfonamides ou carbamates aromatiques d'acrylonitrile et nouveaux derives amides, sulfonamides ou carbamates d'acrylonitrile |
| EP3593820A1 (en) | 2003-05-23 | 2020-01-15 | Nektar Therapeutics | Peg derivatives containing two peg chains |
| WO2005007121A2 (en) | 2003-07-18 | 2005-01-27 | Massachusetts Institute Of Technology | Mutant interleukin-2(il-2) polypeptides |
| US7567215B1 (en) | 2007-10-23 | 2009-07-28 | The United States Of America As Represented By The Secretary Of The Navy | Portable and inflatable antenna device |
| KR102591732B1 (ko) * | 2010-11-12 | 2023-10-19 | 넥타르 테라퓨틱스 | Ｉｌ-2 부분 및 중합체의 접합체 |
| CN109432407A (zh) * | 2011-03-11 | 2019-03-08 | 公共事业救济局-巴黎医院 | 低剂量il-2用于治疗自身免疫相关病症或炎性病症的应用 |
| US10898576B2 (en) * | 2016-03-16 | 2021-01-26 | Yanhui Xie | Glucocorticoid combined with polyethylene glycol-modified interleukin 2 for treating respiratory disease |
-
2019
- 2019-05-20 SG SG11202011242SA patent/SG11202011242SA/en unknown
- 2019-05-20 CR CR20200546A patent/CR20200546A/es unknown
- 2019-05-20 EA EA202092489A patent/EA202092489A1/ru unknown
- 2019-05-20 AU AU2019274409A patent/AU2019274409B2/en active Active
- 2019-05-20 IL IL278528A patent/IL278528B1/en unknown
- 2019-05-20 KR KR1020207033346A patent/KR20210002577A/ko active IP Right Grant
- 2019-05-20 US US17/056,050 patent/US20210205413A1/en active Pending
- 2019-05-20 CN CN201980034052.1A patent/CN112399859A/zh active Pending
- 2019-05-20 WO PCT/US2019/033100 patent/WO2019226538A1/en active Application Filing
- 2019-05-20 JP JP2020564540A patent/JP7235772B2/ja active Active
- 2019-05-20 BR BR112020021564-3A patent/BR112020021564A2/pt unknown
- 2019-05-20 PE PE2020001854A patent/PE20211307A1/es unknown
- 2019-05-20 JO JOP/2020/0290A patent/JOP20200290A1/ar unknown
- 2019-05-20 CA CA3100204A patent/CA3100204A1/en active Pending
- 2019-05-20 EP EP19732788.5A patent/EP3796940A1/en active Pending
-
2020
- 2020-11-18 PH PH12020551976A patent/PH12020551976A1/en unknown
- 2020-11-19 DO DO2020000212A patent/DOP2020000212A/es unknown
- 2020-11-19 CL CL2020003008A patent/CL2020003008A1/es unknown
- 2020-11-20 EC ECSENADI202074392A patent/ECSP20074392A/es unknown
- 2020-11-23 CO CONC2020/0014510A patent/CO2020014510A2/es unknown
-
2022
- 2022-10-06 AU AU2022246440A patent/AU2022246440A1/en active Pending
- 2022-12-23 JP JP2022206250A patent/JP2023052053A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3100204A1 (en) | 2019-11-28 |
| PE20211307A1 (es) | 2021-07-20 |
| JP7235772B2 (ja) | 2023-03-08 |
| IL278528A (es) | 2021-01-31 |
| CR20200546A (es) | 2021-05-18 |
| JP2023052053A (ja) | 2023-04-11 |
| PH12020551976A1 (en) | 2021-09-13 |
| SG11202011242SA (en) | 2020-12-30 |
| AU2019274409A1 (en) | 2020-11-12 |
| CN112399859A (zh) | 2021-02-23 |
| ECSP20074392A (es) | 2021-03-31 |
| US20210205413A1 (en) | 2021-07-08 |
| WO2019226538A1 (en) | 2019-11-28 |
| EP3796940A1 (en) | 2021-03-31 |
| AU2019274409B2 (en) | 2022-07-14 |
| AU2022246440A1 (en) | 2022-11-03 |
| DOP2020000212A (es) | 2021-03-15 |
| IL278528B1 (en) | 2024-06-01 |
| CO2020014510A2 (es) | 2021-03-08 |
| BR112020021564A2 (pt) | 2021-03-02 |
| EA202092489A1 (ru) | 2021-03-16 |
| JP2021523922A (ja) | 2021-09-09 |
| CL2020003008A1 (es) | 2021-07-30 |
| KR20210002577A (ko) | 2021-01-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020551976A1 (en) | SELECTIVE TREG STIMULATOR RUR20kD-IL-2 AND RELATED COMPOSITIONS | |
| WO2020086726A3 (en) | Nerve stimulation for treating migraine and other headache conditions | |
| MX2020008906A (es) | Compuestos con actividad inductora de ferroptosis y métodos de uso de estos. | |
| PH12017500070A1 (en) | Methods of treating cancer using tigit inhibitors and anti-cancer agents | |
| ZA201804513B (en) | Method of treating c3 glomerulopathy | |
| MX2022011546A (es) | Composiciones y metodos para el agotamiento de celulas cd137+. | |
| EA201791518A1 (ru) | Способы лечения заболеваний сетчатки | |
| MX2019005402A (es) | Terapias de combinacion del inhibidor de arginasa. | |
| MX2020011817A (es) | Metodos para tratar el linfoma. | |
| NZ741785A (en) | 3-cyano-1h-1,2,4-triazol-1-yl compounds and uses thereof for the treatment of hiv | |
| MX2021010173A (es) | Compuestos con actividad inductora de ferroptosis y métodos de uso. | |
| WO2019157495A3 (en) | Methods for preventing and/or treating bone loss conditions by modulating irisin | |
| MX2020011254A (es) | Celulas t car anti-bcma para agotamiento de celulas de plasma. | |
| MX2019013862A (es) | Terapia de combinacion. | |
| MX2020008680A (es) | Terapia de combinacion con apilimod y agentes glutamatergicos. | |
| MX2022006073A (es) | Metodos para utilizar anticuerpos anti-trem2. | |
| PH12017500392A1 (en) | Medical treatments based on anamorelin | |
| MX2021013354A (es) | Metodos para tratar y/o prevenir queratosis actinica. | |
| MX2021014905A (es) | Células seguras e invisibles para el sistema inmunitario. | |
| MX2018008903A (es) | COMPOSICIONES Y METODOS DE USO DE ß-HIDROXI-ß-METILBUTIRATO (HMB) PARA MODULAR AUTOFAGIA Y LIPOFAGIA. | |
| PH12020551071A1 (en) | Compositions and methods for treating retinal disorders | |
| MX2020011263A (es) | Metodos y composiciones de agotamiento de celulas t citotoxicas. | |
| MX2020013621A (es) | Composiciones y metodos de tratamiento de vih. | |
| MX2021002982A (es) | Composiciones y metodos para tratar retinitis pigmentosa. | |
| WO2019040105A3 (en) | COMPOUNDS, SALTS THEREOF AND METHODS FOR THE TREATMENT OF DISEASES |